

Medicinal polypharmacology in the clinic: translating the polypharmacolome into therapeutic benefit

Muhammad Rafehi, Marius Möller, Wouroud Ismail Al-Khalil, Sven Marcel Stefan

Angaben zur Veröffentlichung / Publication details:

Rafehi, Muhammad, Marius Möller, Wouroud Ismail Al-Khalil, and Sven Marcel Stefan. 2024. "Medicinal polypharmacology in the clinic: translating the polypharmacolome into therapeutic benefit." *Pharmaceutical Research* 41 (3): 411–17.
<https://doi.org/10.1007/s11095-024-03656-8>.



Medicinal Polypharmacology in the Clinic – Translating the Polypharmacolome into Therapeutic Benefit

Muhammad Rafehi^{1,2} · Marius Möller³ · Wouroud Ismail Al-Khalil² · Sven Marcel Stefan^{4,5,6}

Received: 21 October 2023 / Accepted: 7 January 2024 / Published online: 16 February 2024
© The Author(s) 2024

Abstract

Drugs with multiple targets, often annotated as ‘unselective’, ‘promiscuous’, ‘multitarget’, or ‘polypharmacological’, are widely considered in both academic and industrial research as a high risk due to the likelihood of adverse effects. However, retrospective analyses have shown that particularly approved drugs bear rich polypharmacological profiles. This raises the question whether our perception of the specificity paradigm (‘one drug-one target concept’) is correct – and if specifically multitarget drugs should be developed instead of being rejected. These questions provoke a paradigm shift – regarding the development of polypharmacological drugs not as a ‘waste of investment’, but acknowledging the existence of a ‘lack of investment’. This perspective provides an insight into modern drug development highlighting latest drug candidates that have not been assessed in a broader polypharmacology-based context elsewhere embedded in a historic framework of classical and modern approved multitarget drugs. The article shall be an inspiration to the scientific community to re-consider current standards, and more, to evolve to a better understanding of polypharmacology from a challenge to an opportunity.

Keywords dual targeted therapy · multitarget · polypharmacology · polypharmacy · privileged ligands · target repurposing

Polypharmacology Established in Drug Therapy

Polypharmacology is the research field focusing the drugs and medical applications that have effects on multiple targets. It has grown over the last decades into a distinct

approach on how to tackle human disease, and its development in various research fields including structural and chemical biology, pharmaceutical and medicinal chemistry, as well as molecular and clinical pharmacology has shed light on polypharmacology from various angles. Nowadays, several aspects can be identified:

- ‘structural polypharmacology’ (structural commonalities despite phylogenetic distance of target proteins)

Muhammad Rafehi and Sven Marcel Stefan contributed equally to this work.

✉ Muhammad Rafehi
muhammad.rafehi@med.uni-augsburg.de;
muhammad.rafehi@med.uni-goettingen.de

✉ Sven Marcel Stefan
sven.stefan@uni-luebeck.de
sven.stefan@umlub.pl

¹ Department of Medical Education Augsburg, Augsburg University Medicine, Stenglinstr. 2, 86156 Augsburg, Germany

² Institute of Clinical Pharmacology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany

³ Medical Systems Biology Group, Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck

and University Medical Center Schleswig-Holstein, Ratzeburger Allee 160, 23538 Lübeck, Germany

⁴ Medicinal Chemistry and Systems Polypharmacology, Medical Systems Biology Division, Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck and University Medical Center Schleswig-Holstein, Ratzeburger Allee 160, 23538 Lübeck, Germany

⁵ Department of Pathology, University of Oslo and Oslo University Hospital, Sognsvannsveien 20, 0372 Oslo, Norway

⁶ Department of Biopharmacy, Medical University of Lublin, Chodzki 4a, Lublin 20-093, Poland

- ‘molecular polypharmacology’ (molecular-structural motifs that define the multitargeticity of drugs)
- ‘evolutionary polypharmacology’ (structural and functional commonalities between orthologs of different species)
- ‘functional polypharmacology’ [differential mode(s)-of-action of multitarget drugs with multiple targets based on their particular molecular interaction]
- ‘clinical polypharmacology’ (engagement of multiple targets in a therapeutic setting)

The ‘polypharmacolome’ is the opportunity space between the above-named aspects in which polypharmacological drugs of the future can be developed by medicinal chemists [1, 2]. Thus, ‘medicinal polypharmacology’ represents an additional part of polypharmacology stretching into other important subfields. However, it still appears to be a theoretical concept rather than an established part of today’s research activities in drug development. The specificity paradigm (‘one drug-one target concept’) has manifested itself as the golden standard for many decades, thereby hindering sincere consideration of alternative approaches. Nevertheless, polypharmacology made its way into clinical application, as demonstrated with two examples from different therapeutic areas:


- The development of tyrosine kinase inhibitors (TKIs) was a milestone in advanced anti-cancer therapy around two decades ago. As a matter of fact, the vast majority of TKIs are multitarget drugs that simultaneously target not only one particular (receptor) tyrosine kinase but multiple ones [3]. Three prominent examples are brivanib [inhibiting

fibroblast growth factor (FGF) receptors and vascular endo-thelial growth factor receptors (VEGFRs)], sunitinib [inhibiting colony stimulating factor 1 receptor (CSF1R), FMS-like tyrosine kinase 3 (FLT3), tyrosine-protein kinase KIT (KIT) and tyrosine-protein kinase RET (RET), platelet-derived growth factor receptors α and β (PDGFRA and B), and VEGFR1–3], and vatalanib (inhibiting KIT, PDGFR, and VEGFR) [4–6];

- A much older class of compounds that is genuinely multitargeting is central nervous system-(CNS)-active drugs against psychiatric disorders [7]. These include, for instance, first generation antidepressants such as the tricyclic antidepressant amitriptyline [8–10] or neuroleptics such as ziprasidone [5, 8, 11, 12]. Both drugs inhibit, to a different extent, adrenergic (α R), dopamine (DR), histamine (HR), muscarinic acetylcholine (mAChR), and serotonin receptors (5-HT_R) as well as the solute carriers (SLCs) of the SLC6A subfamily that transport dopamine (DAT), noradrenaline (NAT), and serotonin (SERT). Figure 1 shows the molecular formulae of the aforementioned drugs and their molecular-structural diversity.

Interestingly, the above-named drugs stretch with their bioactivity also into other protein superfamilies. The TKIs brivanib [13, 14], sunitinib [13, 15–17], and vatalanib [15, 18] showed both direct inhibition of ABC transporters and/or efficacy against ABC transporters-expressing cancer cell lines. Additionally, sunitinib demonstrated inhibition against the SLC organic cation transporter 1 (OCT1; *SLC22A1*) [19]. Amitriptyline and ziprasidone, on the other hand, had

Fig. 1 Molecular formulae of approved drugs with polypharmacological profiles.



not only an extended polypharmacological profile against SLC transporters [20, 21], but were also reported to interfere with human [21, 22], murine [23, 24], and bacterial [25] ABC transporters as well. These findings suggest that multitarget agents do not only translate between phylogenetically distant human protein families, but also between species. The translation between species is an important approach in ‘target repurposing’ strategies to discover novel antibiotics [26, 27].

The Immense Potential of Medicinal Polypharmacology

These examples emphasize the tremendous impact that medicinal polypharmacology as the intentional rational development of polypharmacological drugs can have. Clinical indications for which no satisfactory drug therapy is as yet available will benefit in particular from a completely novel drug development approach. In fact, medicinal polypharmacology is advancing in various fields of medical sciences, such as cardiovascular, infectious, malignant, metabolic, neurologic, and neurodegenerative diseases [1, 4, 5, 8, 28, 29].

Interestingly, within the landscape of known small-molecule compounds, drugs by their very nature are comparatively often shown to have polypharmacological profiles [30–32]. One obvious explanation is that drugs were from the very start of both phenotypic and target-based *in vitro* assays the first choice for probing small-molecules toward novel targets / diseases. Thus, drugs were used more often in screenings against other targets than compounds developed for a specific target protein (family). In particular, the latter group of compounds is barely evaluated beyond their distinct target (family) of interest. Another explanation for the large fraction of multitarget agents among approved drugs could also be that the drug evaluation and selection process in clinical trials favors multitarget drugs due to their superior clinical efficacy [30].

While this is only a speculation, it is certainly possible that the clinical picture involves more contributors than the single target at which the drug showed efficacy *in vitro* during the early stage of drug discovery. In other words, only because a possible mode-of-action for a new drug has been identified *in vitro*, it does not necessarily mean that this is the sole mechanism by which it exhibits its therapeutic benefit. Conversely, one could also speculate that these extended polypharmacological profiles of clinical drug candidates, which simultaneously address a network of targets, are indeed essential to achieve the observed therapeutic benefit in a clinical study. Moreover, that these additional drug targets, such as ABC and SLC transporters, in fact also belong to the primary pharmacological targets. Altogether, these

aspects emphasize the immense importance and potential of multitarget drugs in clinical application, and the necessity of widely recognizing this not only in academia but also in the drug developing industry.


Medicinal Polypharmacology in Today’s Drug Discovery

Academic research in the field of medicinal polypharmacology is rapidly growing. The number of polypharmacology-associated publications has seen an exponential increase. For instance, articles with the search term ‘dual targeted therapy’ rose from just over a hundred annually in the early 2000’s to over 2,700 publications in the last year alone. Similarly, ‘multitarget therapy’ or ‘multitarget drug’ increased from a dozen to almost a thousand publications every year during these two decades while the term ‘polypharmacology’ is now associated with over a hundred publications annually.

Expectedly, the majority of these reports were published by academic research groups, however, promising initiatives by a number of pharmaceutical companies emerged that have also realized the potential of polypharmacology. Three notable examples are in the field of pulmonary disorders:

- (i) For the treatment of *asthma bronchiale*, AstraZeneca recently reported the development of a drug candidate with physicochemical properties suitable for an inhalative drug application that inhibits two different subtypes of phosphoinositol 3-kinases (PI3K) in leucocytes [33]. AZD8154 (Fig. 2), as it is referred to, was the result of the intentional combination of the activities of the two series of selective PI3K γ and PI3K δ inhibitors that had previously been developed by AstraZeneca. It was shown to be safe in a randomized phase I clinical trial, with no reports of serious adverse events, and exhibited pharmacokinetic properties suitable for once-daily drug application [34]. However, a subsequent phase II clinical trial has been withdrawn due to “emerging pre-clinical toxicology findings” (www.clinicaltrials.gov, #NCT04187508);
- (ii) For the treatment of chronic obstructive pulmonary disease (COPD), the Italian company Chiesi Farmaceutici in collaboration with Charles River Laboratories very recently combined antagonism at the M₃ mAChR with inhibition of phosphodiesterase 4 (PDE4) in a so-called MAPI drug candidate (compound 10f; Fig. 2) that showed a balanced bronchodilator / anti-inflammatory profile in rats [35].
- (iii) The California-based company Theravance Biopharma, on the other hand, published a few years earlier a so-called MABA, *i.e.*, a muscarinic antago-

Fig. 2 Molecular formulae of polypharmacological drugs and drug candidates.



nist and β_2 adrenergic receptor agonist [36]. Both modes-of-action have been regularly employed in the treatment of COPD using single-mode drugs that demonstrated synergistic effects when given in combination. Theravance Biopharma sought to combine both mechanisms in a single drug, called batenfenterol (also referred to as TD-5959 and GSK961081; Fig. 2). Together with Glaxo-SmithKline, a number of clinical studies have been conducted to investigate the safety, pharmacokinetics, drug-drug interactions, and beneficial combinations, including a very recent phase II study in combination with a glucocorticoid [37].

Another set of clinical indications for which dual- or even triple-target drugs are currently under development is type 2 *diabetes mellitus*, obesity, and comorbidities:

- (i) Tirzepatide (formerly referred to as LY3298176; Fig. 3), a fatty acid modified polypeptide developed by Eli Lilly, is a dual agonist at the receptors for the enteroendocrine incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) [38]. With approved drugs like exenatide, liraglutide, and semaglutide, selective GLP-1 receptor agonism is currently second-line therapy after metformin. However, gastrointestinal




Fig. 3 Amino acid sequences of the polypharmacology-by-design drugs tirzepatide, bamadutide, and retatrutide.

adverse effects prevent dosage increase and thereby higher therapeutic efficacy, especially concerning weight loss. Combining GLP-1 and GIP receptor agonism in a single drug was thus considered to be a possible solution, and this was facilitated by the high degree of sequence similarity between GLP-1 and GIP. Tirzepatide exhibited greater efficacy than selective GLP-1 receptor agonists in several clinical trials as well as a Cochrane meta-analysis [39], and consequently, received approval last year as a first-in-class medication.

- (ii) Another approach to ameliorate the established therapeutic benefit of GLP-1 agonism through polypharmacology is the combination with glucagon receptor agonism. Sanofi-Aventis' drug candidate bamadutide (SAR425899; Fig. 3) successfully passed a number of phase I and one phase II clinical trials [40]. However, another placebo-controlled study evaluating its effects in non-alcoholic fatty liver disease was prematurely terminated due to reasons other than safety concerns (www.clinicaltrials.gov, #NCT034377209, and no further clinical trials have been commenced since.
- (iii) Eli Lilly took it a step further and developed the triple-target drug candidate retatrutide (LY3437943; Fig. 3) that showed agonism at the GLP-1, GIP, and glucagon receptors. It also passed a number of phase I and phase II clinical trials [41–43]. Several phase III studies on patients suffering from type 2 diabetes mellitus and/or obesity with and without cardiovascular disease, osteoarthritis, or chronic kidney disease are currently being conducted (clinicaltrials.gov, accessed October 20, 2023). Thus, retatrutide might very well become another success story of medicinal polypharmacology.

Concluding Remarks

In summary, polypharmacology has always been an integral part of drug therapy, although unintentional and unknowingly until this concept has first been formulated two decades ago. The examples discussed here emphasize the great potential of multitarget drugs and delineate the impact they can have on patients suffering from complex diseases for which the specificity paradigm failed to provide adequate solutions. Nevertheless, deliberate medicinal polypharmacology is still rather an exception than the norm in current drug development. A more widespread awareness and sincere appreciation of polypharmacology and its benefits, especially in the pharmaceutical industry, are crucial to harness its full potential toward more effective drug therapies.

Acknowledgements Muhammad Refehi received funding from the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG; #437446827) and the research program of the University Medical Center Göttingen.

Sven Marcel Stefan was supported by the Walter Benjamin and Research Grant programs of the DFG (#446812474, #504079349 [PANABC]).

Funding Open access funding provided by University of Oslo (incl Oslo University Hospital).

Data Availability This article contains no datasets generated or analyzed during the current study.

Declarations

Conflict of Interest The authors declare no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Stefan SM, Rafehi M. The big data challenge – And how polypharmacology supports the translation from pre-clinical research into clinical use against neurodegenerative diseases and beyond. *Neural Regen Res.* 2024;19(8):1647–8. <https://doi.org/10.4103/1673-5374.387984>.
2. Stefan SM, Rafehi M. Medicinal polypharmacology – exploration and exploitation of the polypharmacolome in modern drug development. *Drug Dev Res.* 2024;85:e22125. <https://doi.org/10.1002/ddr.22125>.
3. Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update. *Pharmacol Res.* 2023;187:106552.
4. Wang Z, Yang B. Polypharmacology. Principles and Methodologies. Springer Nature. 2022. <https://doi.org/10.1007/978-3-031-04998-9>
5. Morphy R, Rankovic Z. Designing Multiple Ligands – Medicinal Chemistry Strategies and Challenges. *Curr Pharm Des.* 2009;15(6):587–600. <https://doi.org/10.2174/138161209787315594>.
6. Zimmermann GR, Lehar J, Keith CT. Multi-target Therapeutics: When the Whole is Greater than the Sum of the Parts. *Drug Discov Today.* 2007;12(1–2):34–42. <https://doi.org/10.1016/j.drudis.2006.11.008>.
7. Stark H. Turning from Monogamy to Strategic Promiscuity. *Drug Discov Today.* 2004;9(17):736–7. [https://doi.org/10.1016/S1359-6446\(04\)03208-8](https://doi.org/10.1016/S1359-6446(04)03208-8).
8. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. *J Med Chem.* 2005;48(21):6523–43. <https://doi.org/10.1021/jm058225d>.
9. Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on

- receptor binding. *Cell Mol Neurobiol.* 1999;19(4):467–89. <https://doi.org/10.1023/a:1006986824213>.
10. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. *J Pharmacol Exp Ther.* 1997;283(3):1305–22.
 11. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. *Eur J Pharmacol.* 2001;425(3):197–201. [https://doi.org/10.1016/s0014-2999\(01\)01188-8](https://doi.org/10.1016/s0014-2999(01)01188-8).
 12. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and receptor binding. *Psychopharmacology (Berl).* 1996;124(1–2):57–73. <https://doi.org/10.1007/BF02245606>.
 13. Stefan SM, Jansson PJ, Pahnke J, Namasivayam V. A Curated Binary Pattern Multitarget Dataset of Focused ATP-binding Cassette Transporter Inhibitors. *Sci Data.* 2022;9(1):446. <https://doi.org/10.1038/s41597-022-01506-z>.
 14. Hofman J, Sorf A, Vagiannis D, Sucha S, Kammerer S, Kupper JH, et al. Brivanib exhibits potential for pharmacokinetic drug-drug interactions and the modulation of multidrug resistance through the inhibition of human ABCG2 drug efflux transporter and CYP450 biotransformation enzymes. *Mol Pharm.* 2019;16(11):4436–50. <https://doi.org/10.1021/acs.molpharmac.9b00361>.
 15. Silbermann K, Stefan SM, Elshawadfy R, Namasivayam V, Wiese M. Identification of thienopyrimidine scaffold as an inhibitor of the ABC transport protein ABCC1 (MRP1) and related transporters using a combined virtual screening approach. *J Med Chem.* 2019;62(9):4383–400. <https://doi.org/10.1021/acs.jmedchem.8b01821>.
 16. Kim J, Kim H, Park SB. Privileged structures: efficient chemical “Navigators” toward unexplored biologically relevant chemical spaces. *J Am Chem Soc.* 2014;136(42):14629–38. <https://doi.org/10.1021/ja508343a>.
 17. Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, et al. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. *Cancer Lett.* 2009;279(1):74–83. <https://doi.org/10.1016/j.canlet.2009.01.027>.
 18. To KK, Poon DC, Wei Y, Wang F, Lin G, Fu LW. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia. *Biochem Pharmacol.* 2015;97(1):27–37. <https://doi.org/10.1016/j.bcp.2015.06.034>.
 19. Chen EC, Khuri N, Liang X, Stecula A, Chien HC, Yee SW, et al. Discovery of competitive and noncompetitive ligands of the organic cation transporter 1 (OCT1; SLC22A1). *J Med Chem.* 2017;60(7):2685–96. <https://doi.org/10.1021/acs.jmedchem.6b01317>.
 20. Matthaei J, Brockmöller J, Steimer W, Pischke K, Leucht S, Kullmann M, et al. Effects of genetic polymorphism in CYP2D6, CYP2C19, and the organic cation transporter OCT1 on amitriptyline pharmacokinetics in healthy volunteers and depressive disorder patients. *Front Pharmacol.* 2021;12: 688950. <https://doi.org/10.3389/fphar.2021.688950>.
 21. Ivanyuk A, Livio F, Biollaz J, Buclin T. Renal drug transporters and drug interactions. *Clin Pharmacokinet.* 2017;56(8):825–92. <https://doi.org/10.1007/s40262-017-0506-8>.
 22. Jiang C, Lee SH, Park JH, Lee JS, Park JW, Kim JR, et al. A Low Dose of aripiprazole has the strongest sensitization effect among 19 repositioned bipolar drugs in P-gp-overexpressing drug-resistant cancer cells. *Anticancer Res.* 2021;41(2):687–97. <https://doi.org/10.21873/anticancer.14820>.
 23. Holthoewer D, Kirschbaum KM, Frisch J, Hiemke C, Schmitt U. Pharmacodynamic effects of aripiprazole and ziprasidone with respect to P-glycoprotein substrate properties. *Pharmacopsychiatry.* 2013;46(5):175–80. <https://doi.org/10.1055/s-0033-1347176>.
 24. Abaut AY, Chevanne F, Le Corre P. Influence of efflux transporters on liver, bile and brain disposition of amitriptyline in mice. *Int J Pharm.* 2009;378(1–2):80–5. <https://doi.org/10.1016/j.ijpharm.2009.05.068>.
 25. Grimsey EM, Fais C, Marshall RL, Ricci V, Ciusa ML, Stone JW, et al. Chlorpromazine and amitriptyline are substrates and inhibitors of the AcrB multidrug efflux pump. *mBio.* 2020;11(3). <https://doi.org/10.1128/mBio.00465-20>
 26. Singh B, Bernatchez JA, McCall LI, Calvet CM, Ackermann J, Souza JM, et al. Scaffold and parasite hopping: discovery of new protozoal proliferation inhibitors. *ACS Med Chem Lett.* 2020;11(3):249–57. <https://doi.org/10.1021/acsmchemlett.9b00453>.
 27. Klug DM, Gelb MH, Pollastri MP. Repurposing strategies for tropical disease drug discovery. *Bioorg Med Chem Lett.* 2016;26(11):2569–76. <https://doi.org/10.1016/j.bmcl.2016.03.103>.
 28. Lillich FF, Imig JD, Proschak E. Multi-target approaches in metabolic syndrome. *Front Pharmacol.* 2020;11:554961. <https://doi.org/10.3389/fphar.2020.554961>.
 29. Chaudhari R, Tan Z, Zhang S. 2.10 - Overview of drug polypharmacology and multitargeted molecular design. *Comprehensive Medicinal Chemistry III.* 2017:259–75. <https://doi.org/10.1016/B978-0-12-409547-2.12323-6>
 30. Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery. *J Med Chem.* 2014;57(19):7874–87. <https://doi.org/10.1021/jm5006463>.
 31. Vulpetti A, Kalliokoski T, Milletti F. Chemogenomics in drug discovery: computational methods based on the comparison of binding sites. *Future Med Chem.* 2012;4(15):1971–9. <https://doi.org/10.4155/fmc.12.147>.
 32. Jalencas X, Mestres J. On the origins of drug polypharmacology. *Med Chem Comm.* 2013;4:80–7. <https://doi.org/10.1039/C2MD20242E>.
 33. Perry MWD, Bjorhall K, Bold P, Brulls M, Borjesson U, Carlsson J, et al. Discovery of AZD8154, a Dual PI3Kγ/δ inhibitor for the treatment of asthma. *J Med Chem.* 2021;64(12):8053–75. <https://doi.org/10.1021/acs.jmedchem.1c00434>.
 34. Sadiq MW, Asimus S, Belvisi MG, Brailsford W, Fransson R, Fuhr R, et al. Characterisation of pharmacokinetics, safety and tolerability in a first-in-human study for AZD8154, a novel inhaled selective PI3Kγ/δ dual inhibitor targeting airway inflammatory disease. *Br J Clin Pharmacol.* 2022;88(1):260–70. <https://doi.org/10.1111/bcp.14956>.
 35. Rizzi A, Amari G, Pivetti F, Delcanale M, Amadei F, Pappani A, et al. Optimization of M(3) antagonist-PDE4 inhibitor (MAPI) dual pharmacology molecules for the treatment of COPD. *J Med Chem.* 2023;66(16):11476–97. <https://doi.org/10.1021/acs.jmedchem.3c01012>.
 36. Hughes AD, Chen Y, Hegde SS, Jasper JR, Jaw-Tsai S, Lee TW, et al. Discovery of (R)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate (TD-5959, GSK961081, Batefenterol): first-in-class dual pharmacology multivalent muscarinic antagonist and beta(2) agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD). *J Med Chem.* 2015;58(6):2609–22. <https://doi.org/10.1021/jm501915g>.
 37. Crim C, Gotfried M, Spangenthal S, Watkins M, Emmett A, Crawford C, et al. A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD. *BMC Pulm Med.* 2020;20(1):119. <https://doi.org/10.1186/s12890-020-1153-7>.
 38. Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1

- receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. *Mol Metab.* 2018;18:3–14. <https://doi.org/10.1016/j.molmet.2018.09.009>.
39. Dutta D, Surana V, Singla R, Aggarwal S, Sharma M. Efficacy and Safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: a cochrane meta-analysis. *Indian J Endocrinol Metab.* 2021;25(6):475–89. https://doi.org/10.4103/ijem.ijem_423_21.
40. Schiavon M, Visentin R, Gobel B, Riz M, Cobelli C, Klabunde T, et al. Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide. *Diabetes Obes Metab.* 2021;23(8):1795–805. <https://doi.org/10.1111/dom.14394>.
41. Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. *Lancet.* 2023;402(10401):529–44. [https://doi.org/10.1016/S0140-6736\(23\)01053-X](https://doi.org/10.1016/S0140-6736(23)01053-X).
42. Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, et al. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. *N Engl J Med.* 2023;389(6):514–26. <https://doi.org/10.1056/NEJMoa2301972>.
43. Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised. Multiple-ascending Dose Trial *Lancet.* 2022;400(10366):1869–81. [https://doi.org/10.1016/S0140-6736\(22\)02033-5](https://doi.org/10.1016/S0140-6736(22)02033-5).

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.